PHP
NBIX icon

Parkman Healthcare Partners’s Neurocrine Biosciences NBIX Stock Holding History

Parkman Healthcare Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1M Sell
99,069
-15,643
-14% -$2.08M 1.35% 25
2025
Q4 		$16.3M Sell
114,712
-27,110
-19% -$3.93M 1.55% 20
2025
Q3 		$19.9M Sell
141,822
-24,188
-15% -$3.28M 2.08% 15
2025
Q2 		$20.9M Sell
166,010
-2,372
-1% -$272K 2.4% 11
2025
Q1 		$18.6M Buy
168,382
+52,655
+45% +$6.67M 2.21% 13
2024
Q4 		$15.8M Sell
115,727
-14,113
-11% -$1.75M 2.1% 15
2024
Q3 		$15M Buy
129,840
+14,670
+13% +$2.01M 1.91% 17
2024
Q2 		$15.9M Sell
115,170
-16,781
-13% -$2.3M 2.12% 12
2024
Q1 		$18.2M Sell
131,951
-8,165
-6% -$1.12M 2.23% 11
2023
Q4 		$18.5M Buy
140,116
+56,271
+67% +$6.48M 2.6% 10
2023
Q3 		$9.43M Sell
83,845
-55,890
-40% -$5.89M 1.73% 15
2023
Q2 		$13.2M Sell
139,735
-78,103
-36% -$7.63M 2.28% 13
2023
Q1 		$22M Buy
217,838
+101,505
+87% +$10.6M 4.8% 2
2022
Q4 		$13.9M Sell
116,333
-1,067
-0.9% -$125K 3.7% 4
2022
Q3 		$12.5M Buy
117,400
+31,811
+37% +$3.23M 3.55% 5
2022
Q2 		$8.34M Buy
85,589
+22,355
+35% +$2.06M 3.07% 9
2022
Q1 		$5.93M Buy
+63,234
New +$5.36M 1.73% 20
2020
Q4 		– Sell
-132,544
Closed -$12.7M – 93
2020
Q3 		$12.7M Buy
132,544
+11,018
+9% +$1.27M 3.37% 3
2020
Q2 		$14.8M Sell
121,526
-7,000
-5% -$774K 4.18% 1
2020
Q1 		$11.1M Sell
128,526
-26,899
-17% -$2.63M 5.16% 2
2019
Q4 		$16.7M Buy
+155,425
New +$16.3M 4.82% 2

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parkman Healthcare Partners's NBIX Position: Q1 2026 in Review

Parkman Healthcare Partners reduced its Neurocrine Biosciences (NBIX) stake by 14% in Q1 2026, selling an estimated $2.08M and leaving 99,069 shares worth $13.1M. The position accounts for 1.35% of the portfolio, ranked #25.

Parkman Healthcare Partners first reported a position in NBIX in Q4 2019 and has held it in 21 quarters since. The position peaked at $22M in Q1 2023. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Parkman Healthcare Partners held 99,069 shares of Neurocrine Biosciences worth $13.1M as of Q1 2026.
  • Parkman Healthcare Partners sold 15,643 Neurocrine Biosciences shares in Q1 2026, an estimated $2.08M.
  • Neurocrine Biosciences made up 1.35% of Parkman Healthcare Partners's portfolio in Q1 2026, its #25 holding.
  • Parkman Healthcare Partners first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 21 quarters since.
  • Parkman Healthcare Partners's Neurocrine Biosciences position peaked at $22M in Q1 2023.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.